A new form of proton therapy—designed to deliver cancer-killing radiation therapy in less than a second, through fewer sessions, with potentially less risk of damaging side effects—is now being tested in a phase 1 clinical trial at the Abramson Cancer Center of the University of Pennsylvania. Known as FLASH proton therapy, the feasibility study represents the first time that the "conformal," or precise 3D targeting, version of the technique has been tested in human patients in the United States.
First Human Clinical Trial of Precision FLASH Proton Therapy Begins
A new FLASH proton therapy is being tested in a phase 1 clinical trial at the University of Pennsylvania, marking the first human trial of this precise cancer treatment in the U.S. This advancement in cancer treatment could have implications for Iran, particularly in the context of healthcare advancements and potential collaborations in medical research.
👥 Key Players
📰 What Happened
The first human clinical trial of FLASH proton therapy, a new cancer treatment method, has begun at the Abramson Cancer Center. This technique aims to deliver radiation therapy more quickly and with fewer side effects.
- FLASH proton therapy delivers radiation in less than a second.
- This is the first time this precise targeting method is being tested on human patients in the U.S.
💡 Why It Matters
📚 Background
Proton therapy is an advanced form of radiation treatment that targets tumors more precisely than traditional methods, potentially reducing side effects. FLASH therapy aims to further enhance this by delivering treatment in an ultra-fast manner.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%